trending Market Intelligence /marketintelligence/en/news-insights/trending/u0HaJTeY35eQFtmUVVPq2Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novo Nordisk, Teva settle patent lawsuit involving diabetes drug's copycat

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Novo Nordisk, Teva settle patent lawsuit involving diabetes drug's copycat

Novo Nordisk A/S said it settled a patent lawsuit against Teva Pharmaceutical Industries Ltd., which was looking to a launch a generic version of diabetes drug Victoza in the U.S.

Under the deal, the Danish drugmaker gave Israel-based generic-medicine maker Teva a license to launch a generic version of Victoza on Dec. 22, 2023.

Teva can launch the copycat earlier in certain cases, but not before March 22, 2023. It may launch its medicine sooner if Victoza's patents are declared invalid or a rival generic version of the drug enters the market.

The agreement, whose terms are confidential, is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Novo Nordisk's Victoza, also known as liraglutide, generated 2018 sales of 24.33 billion Danish kroner.

As of March 15, US$1 was equivalent to 6.59 Danish kroner, according to S&P Global Market Intelligence.